LDE225

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Advanced Solid Tumor Cancers

Conditions

Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma

Trial Timeline

Oct 1, 2010 → Oct 1, 2013

NCT ID

NCT01208831

About LDE225

LDE225 is a phase 1 stage product being developed by Novartis for Advanced Solid Tumor Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT01208831. Target conditions include Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02195973	Phase 1	Completed	Sep 1, 2014	Sep 30, 2017	Recurrent Ovarian Cancer
NCT02151864	Phase 1	Completed	Jul 1, 2014	Sep 1, 2017	Hepatocellular Carcinoma
NCT02086513	Phase 1	Terminated	Apr 1, 2014	Dec 1, 2016	Graft Versus Host Disease
NCT02002689	Phase 2	Terminated	Feb 1, 2014	Mar 1, 2015	PTCH1 or SMO Activated Solid and Hematologic Tumors
NCT01826214	Phase 2	Completed	May 1, 2013	May 1, 2015	Acute Leukemias
NCT01764776	Phase 1	Completed	Mar 1, 2013	Mar 1, 2015	Normal Hepatic Function
NCT01529450	Pre-clinical	Completed	Feb 1, 2012	Aug 1, 2013	Basal Cell Carcinoma
NCT01327053	Phase 2	Completed	Jun 29, 2011	Jun 29, 2018	Basal Cell Carcinoma
NCT01125800	Phase 1/2	Completed	Feb 1, 2011	Oct 1, 2014	Medulloblastoma
NCT01208831	Phase 1	Completed	Oct 1, 2010	Oct 1, 2013	Advanced Solid Tumor Cancers
NCT00880308	Phase 1	Completed	Mar 1, 2009	Jul 1, 2013	Advanced Solid Tumor Cancers

Competing Products

20 competing products in Advanced Solid Tumor Cancers

See all competitors

Product	Company	Stage	Hype Score
AK-105	Akeso	Phase 1	32
AFM24 + Atezolizumab 840 MG in 14 ML Injection	Affimed	Phase 1/2	33
EXS21546	Biotrial	Phase 1/2	33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)	Syros Pharmaceuticals	Phase 1	25
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	52
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	52
NBTXR3	Nanobiotix	Phase 1/2	36
pegfilgrastim + LY2523355	Eli Lilly	Phase 1	33
SON-1010	Sonnet BioTherapeutics	Phase 1	28
SON-1010	Sonnet BioTherapeutics	Phase 1/2	36
BT1718	Bicycle Therapeutics	Phase 1/2	33
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	44
IMC-18F1	Eli Lilly	Phase 1	33
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	33
OKI-179	OnKure Therapeutics	Phase 1	25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib	OnKure Therapeutics	Phase 1	25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + Docetaxel	Eli Lilly	Phase 1/2	41
LY3434172	Eli Lilly	Phase 1	33
ACR-2316	Acrivon Therapeutics	Phase 1	25
BBP-398	LianBio	Phase 1	25

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved